A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years.

Trial Profile

A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs PF 5212366 (Primary)
  • Indications Meningococcal meningitis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 11 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top